Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system.
Sullivan JM, Mazur C, Wolf DA, Horky L, Currier N, Fitzsimmons B, Hesterman J, Pauplis R, Haller S, Powers B, Tayefeh L, DeBrosse-Serra B, Hoppin J, Kordasiewicz H, Swayze EE, Verma A. J Transl Med. 2020 Aug 8;18(1):309. Pubmed
The dose threshold for nanoparticle tumour delivery
Ouyang B, Poon W, Zhang YN, Lin ZP, Kingston BR, Tavares AJ, Zhang Y, Chen J, Valic MS, Syed AM, MacMillan P, Couture-Senécal J, Zheng G, Chan WCW. Nat Mater. 2020 Aug 10. Pubmed
Direct Delivery of Antisense Oligonucleotides to the Middle and Inner Ear Improves Hearing and Balance in Usher Mice
Lentz JJ, Pan B, Ponnath A, Tran CM, Nist-Lund C, Galvin A, Goldberg H, Robillard KN, Jodelka FM, Farris HE, Huang J, Chen T, Zhu H, Zhou W, Rigo F, Hastings ML, Géléoc GSG. Mol Ther. 2020 Aug 5:S1525-0016(20)30412-3. Pubmed
Increased PIP3 activity blocks nanoparticle mRNA delivery.
Paunovska K, Da Silva Sanchez A, Foster MT, Loughrey D, Blanchard EL, Islam FZ, Gan Z, Mantalaris A, Santangelo PJ, Dahlman JE. Sci Adv. 2020 Jul 22;6(30):eaba5672. Pubmed
Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptide.
Nikan M, Tanowitz M, Dwyer CA, Jackson M, Gaus H, Swayze E, Rigo F, Seth PP, Prakash TP. J Med Chem. 2020 Jul 17. Pubmed
Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
Debacker AJ, Voutila J, Catley M, Blakey D, Habib N. Mol Ther. 2020 Jun 17:S1525-0016(20)30305-1. Pubmed
Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
Wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ. Nat Commun. 2020 Jun 26;11(1):3232. Pubmed
Defining the Design Parameters for in Vivo Enzyme Delivery Through Protein Spherical Nucleic Acids
Kusmierz CD, Bujold KE, Callmann CE, Mirkin CA. ACS Cent Sci. 2020 May 27;6(5):815-822. Pubmed
Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial
Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H, Satou Y, Yamashita T, Hoffman EP; CINRG DNHS Investigators. JAMA Neurol. 2020 May 26 Pubmed
Aptamer-T Cell Targeted Therapy for Tumor Treatment Using Sugar Metabolism and Click Chemistry
Liu CG, Wang Y, Liu P, Yao QL, Zhou YY, Li CF, Zhao Q, Liu GH, Zhang XL. ACS Chem Biol. 2020 May 28. Pubmed
